A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA.

• DOI: 10.1073/pnas.93.8.3176
• Publication Date: 2002-07-26T14:35:07Z
• Authors: J G Lewis; K Y Lin; A Kothavale; W M Flanagan; M D Matteucci; R B DePrince; R A Mook; R W Hendren; R W Wagner
• Keywords: Antisense therapy

Development of antisense technology has focused in part on creating improved methods for delivering oligodeoxynucleotides (ODNs) to cells. In this report, we describe a cationic lipid that, when formulated with the fusogenic dioleoylphosphatidyliethanolamine, greatly improves cellular uptake properties ODNs, as well plasmid DNA. This formulation, termed GS 2888 cytofectin, (i) efficiently transfects ODNs and plasmids into many cell types presence or absence 10% serum medium, (ii) uses 4- 10-fold lower concentration agent compared commercially available Lipofectin liposome, (iii) is > = 20-fold more effective at eliciting effects Lipofectin. Here show using cytofectin together C-5 propynyl pyrimidine phosphorothioate which achieve inhibition gene expression low nanomolar concentrations ODN. expands utility their use understanding function offers potential its DNA delivery applications vivo.